YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.

Other languages YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Equities

1558

CNE1000023R6

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
12.8 ^HKD	+2.40%		+3.56%	+34.88%

09/04	Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	MT
01/04	Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	09/04
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	01/04
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023	29/03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023	13/03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023	12/03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement	29/11
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts	08/11
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China	26/23/26
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration	25/23/25
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes	08/23/08
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales	01/23/01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug	16/23/16
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets	15/23/15
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director	14/23/14
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%	27/23/27
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	26/23/26
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone	06/23/06
HEC Chang Jiang Pharma Completes Equity Transfer in Unit	28/23/28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Equities

1558

CNE1000023R6

Other languages

Filters